Article

Frovatriptan for the prevention of postdural puncture headache.

Department of Clinical Neurology, Istituto Nazionale Neurologico C. Besta, Milano, Italy.
Cephalalgia (impact factor: 3.43). 08/2007; 27(7):809-13. DOI:10.1111/j.1468-2982.2007.01327.x pp.809-13
Source: PubMed

ABSTRACT Efficacy of 5-day treatment with oral frovatriptan 2.5 mg/die for the prophylaxis of post-dural puncture headache (PDPH) was tested in 50 in-patients. A mild headache occurred in 7 (14%) patients for a total of 9 days (p < 0.01 vs. no-PDPH). Most episodes of PDPH occurred in the first days of treatment (only 1 patient had headache at dismissal): 5 patients had only 1 episode, while 2 had headache for 2 consecutive days. No other symptoms were recorded. Occurrence of PDPH in a subgroup of 6 (12%) patients previously submitted to a diagnostic lumbar puncture was also examined: 4 of them reported a PDPH on the previous lumbar puncture in absence of triptans. In only 1 of these 4 patients PDPH recurred under treatment with frovatriptan. In conclusion, our non-randomized open-label study suggests efficacy of oral frovatriptan for PDPH prevention. These results need to be confirmed in a randomized, controlled, double-blind study.

0 0
 · 
0 Bookmarks
 · 
33 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1 patient
 
2 consecutive days
 
4 patients PDPH recurred
 
5 patients
 
5-day treatment
 
50 in-patients
 
9 days
 
diagnostic lumbar puncture
 
double-blind study
 
efficacy
 
first days
 
no-PDPH
 
non-randomized open-label study
 
oral frovatriptan 2.5 mg/die
 
PDPH
 
PDPH prevention
 
post-dural puncture headache
 
previous lumbar puncture
 
randomized
 
subgroup